| 產(chǎn)品描述： | Tenovin-6, an analog of Tenovin-1 (HY-13423), is an activator of p53 transcriptional activity. Tenovin-6 inhibits the protein deacetylase activities of purified human SIRT1, SIRT2, and SIRT3 with IC50s of 21 μM, 10 μM, and 67 μM, respectively. Tenovin-6 also inhibits dihydroorotate dehydrogenase (DHODH) |
| 靶點(diǎn)： |
SIRT2:10 μM (IC50);SIRT1:21 μM (IC50);SIRT3:67 μM (IC50);HDAC8;MDM-2/p53;Dehydrogenase;Sirtuin;Autophagy |
| 體內(nèi)研究： |
Tenovin-6 (50 mg/kg, i.p.) inhibits the growth of tumor in mice |
| 參考文獻(xiàn)： |
1. Lain S, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell. 2008 May;13(5):454-63. 2. Ladds MJGW, et al. Exploitation of DHODH and p53 activation as therapeutic targets - a case study in polypharmacology [published online ahead of print, 2020 Sep 8]. J Biol Chem. 2020;jbc.RA119.012056. 3. Dai W, et al. Class III-specific HDAC inhibitor Tenovin-6 induces apoptosis, suppresses migration and eliminates cancer stem cells in uveal melanoma. Sci Rep. 2016 Mar 4;6:22622. 4. Yuan H, et al. Tenovin-6 impairs autophagy by inhibiting autophagic flux. Cell Death Dis. 2017 Feb 9;8(2):e2608. 5. Yuan H, et al. Tenovin-6 inhibits proliferation and survival of diffuse large B-cell lymphoma cells by blocking autophagy. Oncotarget. 2017 Feb 28;8(9):14912-14924. |
| 溶解性： |
DMSO : ≥ 31 mg/mL (68.19 mM) |
| 保存條件： |
2-8℃ |
| 配置溶液濃度參考： |
|
1mg |
5mg |
10mg |
| 1 mM |
2.2 ml |
10.998 ml |
21.996 ml |
| 5 mM |
0.44 ml |
2.2 ml |
4.399 ml |
| 10 mM |
0.22 ml |
1.1 ml |
2.2 ml |
| 50 mM |
0.044 ml |
0.22 ml |
0.44 ml |
|
| 注意： |
部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。 |
上海工商
危險品化學(xué)品經(jīng)營許可證（不帶存儲）
營業(yè)執(zhí)照(三證合一)
北京